UniProt P01375
Tumor necrosis factor (P01375)
Tumor necrosis factor (UniProt P01375): 63 experimental structures on GenesisL1, 15 ligands bound, 35 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P01375
- Protein
- Tumor necrosis factor
- Experimental structures
- 63
- Predicted models
- 0
- Ligands
- 15
- Pockets
- 35 · 4 records with a druggable one
Structures
63 records of P01375 in the MolNFT archive: 63 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1A8M | Tumor necrosis factor alpha, R31D mutant | x-ray diffraction | A, B, C | — | — |
| 1A8M | Tumor necrosis factor alpha, R31D mutant | x-ray diffraction | A, B, C | — | — |
| 1TNF | The structure of tumor necrosis factor-alpha at 2.6 ångströms resolution. implications for receptor… | x-ray diffraction | A, B, C | — | — |
| 1TNF | The structure of tumor necrosis factor-alpha at 2.6 ångströms resolution. implications for receptor… | x-ray diffraction | A, B, C | — | — |
| 2AZ5 | Crystal Structure of TNF-alpha with a small molecule inhibitor | x-ray diffraction | A, B, C, D | — | — |
| 2AZ5 | Crystal structure of TNF-alpha with a small molecule inhibitor | x-ray diffraction | A, B, C, D | — | — |
| 2E7A | TNF Receptor Subtype One-selective TNF Mutant with Antagonistic Activity | x-ray diffraction | A, B, C | — | — |
| 2E7A | TNF receptor subtype one-selective TNF mutant with antagonistic activity | x-ray diffraction | A, B, C | — | — |
| 2TUN | Conformational changes in the (ala-84-val) mutant of tumor necrosis factor | x-ray diffraction | A, B, C, D, E, F | — | — |
| 2TUN | Conformational changes in the (ala-84-val) mutant of tumor necrosis factor | x-ray diffraction | A, B, C, D, E, F | — | — |
| 2ZJC | TNFR1 selectve TNF mutant; R1-6 | x-ray diffraction | A, B, C | — | — |
| 2ZJC | TNFR1 selectve TNF mutant; R1-6 | x-ray diffraction | A, B, C | — | — |
| 2ZPX | TNF Receptor Subtype One-selective TNF Mutant with Antagonistic Activity; R1antTNF-T8 | x-ray diffraction | A, B, C | — | — |
| 2ZPX | TNF receptor subtype one-selective TNF mutant with antagonistic activity; R1ANTTNF-T8 | x-ray diffraction | A, B, C | — | — |
| 3ALQ | Crystal structure of TNF-TNFR2 complex | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3ALQ | Crystal structure of TNF-TNFR2 complex | x-ray diffraction | A, B, C, D, E, F | — | — |
| 3IT8 | Crystal structure of TNF alpha complexed with a poxvirus MHC-related TNF binding protein | x-ray diffraction | A, B, C, G, H, I | — | — |
| 3IT8 | Crystal structure of TNF alpha complexed with a poxvirus MHC-related TNF binding protein | x-ray diffraction | A, B, C, G, H, I | — | — |
| 3L9J | Selection of a novel highly specific TNFalpha antagonist: Insight from the crystal structure of the… | x-ray diffraction | T | — | — |
| 3L9J | Selection of a novel highly specific tnfalpha antagonist: insight from the crystal structure of the… | x-ray diffraction | T | — | — |
| 3WD5 | Crystal structure of TNFalpha in complex with Adalimumab Fab fragment | x-ray diffraction | A | — | — |
| 3WD5 | Crystal structure of tnfalpha in complex with adalimumab Fab fragment | x-ray diffraction | A | — | — |
| 4G3Y | Crystal structure of TNF-alpha in complex with Infliximab Fab fragment | x-ray diffraction | C | — | — |
| 4G3Y | Crystal structure of TNF-alpha in complex with infliximab Fab fragment | x-ray diffraction | C | — | — |
| 4TSV | High resolution crystal structure of a human TNF-alpha mutant | x-ray diffraction | A | — | — |
| 4TSV | High resolution crystal structure of a human TNF-alpha mutant | x-ray diffraction | A | — | — |
| 4TWT | Human TNFa dimer in complex with the semi-synthetic bicyclic peptide M21 | x-ray diffraction | A, B, C, D | — | — |
| 4TWT | Human tnfa dimer in complex with the semi-synthetic bicyclic peptide M21 | x-ray diffraction | A, B, C, D | — | — |
| 5M2I | Structure of human tumor necrosis factor (TNF) in complex with the llama VHH1 | x-ray diffraction | A, B, C, D, E, F | — | — |
| 5M2J | Complex between human TNF alpha and Llama VHH2 | x-ray diffraction | A | — | 2 (best 0.48) |
| 5M2J | Complex between human TNF alpha and llama VHH2 | x-ray diffraction | A | — | — |
| 5M2M | Complex between human TNF alpha and llama VHH3 | x-ray diffraction | A, B, C, G, I, M | — | — |
| 5MU8 | Human TNF-alpha in complex with JNJ525 | x-ray diffraction | A, B, C, D, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s, t, u, v, w | JNI | — |
| 5MU8 | Human TNF-alpha in complex with JNJ525 | x-ray diffraction | A, B, C, D, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s, t, u, v, w | JNI | — |
| 5TSW | High resolution crystal structure of a human TNF-alpha mutant | x-ray diffraction | A, B, C, D, E, F | — | 6 (best 0.76) |
| 5TSW | High resolution crystal structure of a human TNF-alpha mutant | x-ray diffraction | A, B, C, D, E, F | — | — |
| 5UUI | Crystal structure of spin-labeled T77C tnfa | x-ray diffraction | A | MTN | — |
| 5YOY | Crystal structure of the human tumor necrosis factor in complex with golimumab fv | x-ray diffraction | A, B, C, J, K, L | — | — |
| 6OOY | Asymmetric htnf-alpha | x-ray diffraction | A, B, C | A7M | — |
| 6OOZ | Asymmetric htnf-alpha | x-ray diffraction | A, B, C | CL, A6Y | — |
| 6OP0 | Asymmetric hTNF-alpha | x-ray diffraction | A, B, C | A7A | 4 (best 0.81) |
| 6OP0 | Asymmetric htnf-alpha | x-ray diffraction | A, B, C | A7A | — |
| 6RMJ | Crystal structure of human ngr-TNF | x-ray diffraction | A, B, C | — | — |
| 6X81 | Crystal Structure of TNFalpha with isoquinoline compound 2 | x-ray diffraction | A, B, C, D, E, F | UTJ | 13 (best 0.85) |
| 6X81 | Crystal structure of tnfalpha with isoquinoline compound 2 | x-ray diffraction | A, B, C, D, E, F | UTJ | — |
| 6X82 | Crystal structure of tnfalpha with isoquinoline compound 4 | x-ray diffraction | A, B, C, D, E, F | UTM | — |
| 6X83 | Crystal Structure of TNFalpha with fragment compound 6 | x-ray diffraction | A, B, C, D, E, F | UTS | 10 (best 0.86) |
| 6X83 | Crystal structure of tnfalpha with fragment compound 6 | x-ray diffraction | A, B, C, D, E, F | UTS | — |
| 6X85 | Crystal structure of tnfalpha with indolinone compound 9 | x-ray diffraction | A, B, C, D, E, F | UTV | — |
| 6X86 | Crystal structure of tnfalpha with indolinone compound 11 | x-ray diffraction | A, B, C, D, E, F | UTY | — |
| 7ASY | Transmembrane helix of tumor necrosis factor alpha in trifluorethanol | solution nmr | A | — | — |
| 7AT7 | Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, S34P mutant | solution nmr | A | — | — |
| 7AT7 | Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, S34P mutant | solution nmr | A | — | — |
| 7ATB | Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, AGALLL mutant | solution nmr | A | — | — |
| 7ATB | Transmembrane helix of tumor necrosis factor alpha in trifluorethanol, agalll mutant | solution nmr | A | — | — |
| 7JRA | Human TNF-alpha in complex with 2-[5-(3-chloro-4-{[(1R)-1-(2… | x-ray diffraction | A, B, C | VGY | — |
| 7KP9 | Asymmetric htnf-alpha | x-ray diffraction | A, B, C | A7G | — |
| 7KPA | Asymmetric htnf-alpha | x-ray diffraction | A, B, C | D84 | — |
| 7KPB | Mtnf-alpha HTNFR1 complex | x-ray diffraction | A, B, C | D84 | — |
| 7QLF | Conformational ensemble of solnatide in solution | solution nmr | A | — | — |
3 records more on the page itself.
Ligands
- A7A · (R)-{1-[(2,5-dimethylphenyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-2-yl}(pyridin-4-yl) methanol · in 2 records
- D84 · 5-(1-{[2-(difluoromethoxy)phenyl]methyl}-2-{[3-(2-oxopyrrolidin-1-yl)phenoxy]methyl}-1H-benzimidazol-6-yl)pyridin-2(1H)-one · in 2 records
- JNI · ~{N}4-(phenylmethyl)-~{N}4-[2-[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]phenyl]pyrimidine-2,4-diamine · in 2 records
- UTJ · [4-(isoquinolin-8-yl)phenyl]acetonitrile · in 2 records
- UTS · 1-benzyl-1H-benzimidazole · in 2 records
- A6Y · (S)-{1-[(2,5-dimethylphenyl)methyl]-1H-benzimidazol-2-yl}(pyridin-4-yl)methanol · in 1 record
- A7G · 1-{[2-(difluoromethoxy)phenyl]methyl}-2-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-benzimidazole · in 1 record
- A7M · {1-[(2,5-dimethylphenyl)methyl]-1H-benzimidazol-2-yl}methanol · in 1 record
- CL · Chloride ion · in 1 record
- K · Potassium ion · in 1 record
- MTN · S-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate · in 1 record
- UTM · 8-[4-(2-{5-[(4-methylpiperazin-1-yl)methyl]-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)phenoxy}ethyl) phenyl]isoquinoline · in 1 record
- UTV · 1-{[2-(difluoromethoxy)phenyl]methyl}-2,2-dimethyl-1,2-dihydro-3H-indol-3-one · in 1 record
- UTY · 3-[(6-{2-[(3R)-4-(hydroxyacetyl)-3-methylpiperazin-1-yl]pyrimidin-5-yl}-2,2-dimethyl-3-oxo-2,3-dihydro-1H-indol-1-yl)methyl]pyridine-2-carbonitrile · in 1 record
- VGY · 2-[5-(3-chloro-4-{[(1R)-1-(2-fluorophenyl) ethyl]amino}quinolin-6-yl)pyrimidin-2-yl]propan-2-ol · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.